HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting

BOSTON, Feb. 26, 2026 /PRNewswire/ — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory pockets, today announced it will present preclinical data from the Company’s interferon regulatory factor 5 (IRF5) program in a poster presentation at the 15^th European Lupus Meeting taking place March 4-7, 2026, in Lisbon, Portugal.

Presentation details are as follows:

Title: Preclinical Evaluation of IRF5 Small Molecule Inhibitors with Potent Activity in Lupus-Relevant Systems
Session: Poster Session 11: New Therapies, Including Biologics, Targeted Drugs, and Cell Therapies
Session Date and Time: Fri., Mar. 6, 7:30-18:15 GMT
Location: Poster Area

About HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. is a biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called “natural hotspots.” These pockets are decisive in controlling a protein’s cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology. The Company’s proprietary Smart Allostery platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots, as well as tailored pharmacology toolkits and bespoke chemistry to drive the rapid discovery of novel hotspot-targeted small molecules. Leveraging this approach, HotSpot is building a broad pipeline of novel allosteric therapies for the treatment of autoimmune diseases. To learn more, visit www.hotspotthera.com.

HotSpot Investor & Media Contact:
Natalie Wildenradt
nwildenradt@hotspotthera.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/hotspot-therapeutics-to-present-preclinical-data-from-small-molecule-irf5-inhibitor-program-at-15th-european-lupus-meeting-302697514.html

SOURCE HotSpot Therapeutics